Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient

Influenza Other Respir Viruses. 2013 Nov;7(6):904-8. doi: 10.1111/irv.12108. Epub 2013 Mar 29.

Abstract

A minor viral population of oseltamivir-resistant A(H3N2) viruses (E119V neuraminidase mutation) was selected and maintained in a continually infected immunocompromised child following initial oseltamivir treatment. A subsequent course of oseltamivir given 7 weeks later rapidly selected for the E119V variant resulting in a near-pure population of the resistant virus. The study highlights the challenges of oseltamivir treatment of immunocompromised patients that are continually shedding virus and demonstrates the ability of the E119V oseltamivir-resistant virus to be maintained for prolonged periods even in the absence of drug-selective pressure.

Keywords: E119V NA mutation; immunocompromised; influenza; oseltamivir resistance.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Child, Preschool
  • Drug Resistance, Viral*
  • Humans
  • Immunocompromised Host
  • Influenza A Virus, H3N2 Subtype / drug effects*
  • Influenza A Virus, H3N2 Subtype / genetics
  • Influenza A Virus, H3N2 Subtype / isolation & purification*
  • Influenza, Human / drug therapy*
  • Influenza, Human / virology*
  • Male
  • Mutation, Missense
  • Oseltamivir / pharmacology
  • Oseltamivir / therapeutic use*
  • Selection, Genetic

Substances

  • Antiviral Agents
  • Oseltamivir